10x Genomics (TXG) Misses Q4 EPS by 9c, provides guidance

10x Genomics (NASDAQ: TXG) reported Q4 EPS of ($0.40), $0.09 worse than the analyst estimate of ($0.31). Revenue for the quarter came in at $165 million versus the consensus estimate of $153.44 million.

GUIDANCE:

10x Genomics sees Q1 2025 revenue of $610-630 million, versus the consensus of $630.4 million.

For earnings history and earnings-related data on 10x Genomics (TXG) click here.

You May Also Be Interested In

• Primoris cuts 2026 outlook on renewables cost overruns, COO exits
• Qualcomm (QCOM) PT Raised to $195 at BofA Securities
• Lockheed Martin wins $83 million Army missile contract